XENON PHARMACEUTICALS INC. (XENE) Total liabilities 2016–2025
XENON PHARMACEUTICALS INC. (XENE) total liabilities at each fiscal year-end, per SEC filings.
$51.4MFY2025 · since FY2016: $3.6M → $51.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $51.4M | +18.9% |
| FY2024 | $43.2M | +17.2% |
| FY2023 | $36.9M | +12.9% |
| FY2022 | $32.6M | +48.6% |
| FY2021 | $22.0M | +23.2% |
| FY2020 | $17.8M | -68.0% |
| FY2019 | $55.7M | — |
| FY2017 | $10.2M | +184.1% |
| FY2016 | $3.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More XENE financial trends
XENE RevenueXENE Net incomeXENE Net marginXENE Gross profitXENE Gross marginXENE Operating incomeXENE Operating marginXENE Operating cash flowXENE Free cash flowXENE Capital expendituresXENE Return on equityXENE Stock buybacksXENE Dividends paidXENE Total assetsXENE Shareholders’ equityXENE overview →